Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 2/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16556644 | 0.89 | ADORA3 (0.41) | CCNE2CCNE1CDK2ADORA3 | |
| SCHEMBL98749 | 0.86 | CCNE2 (0.54) | CCNE2CCNE1CDK2MAPTPOLB | |
| SCHEMBL99099 | 0.84 | CCNE2 (0.57) | CCNE2CCNE1CDK2POLBCTSB | |
| SCHEMBL99387 | 0.82 | CCNE1 (0.49) | CCNE2CCNE1CDK2ADORA3ADORA1 | |
| SCHEMBL97640 | 0.81 | CCNE2 (0.41) | CCNE2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL99854 | 0.81 | CCNE2 (0.53) | CCNE2CCNE1CDK2KDM4EMAPT | |
| SCHEMBL97934 | 0.78 | CCNE2 (0.46) | CCNE2CCNE1CDK2KDM4EDAO | |
| SCHEMBL97584 | 0.78 | CCNE2 (0.46) | CCNE2CCNE1CDK2KDM4EDAO | |
| SCHEMBL98797 | 0.77 | CCNE2 (0.45) | CCNE2CCNE1CDK2KDM4EDAO | |
| SCHEMBL100715 | 0.77 | CCNE2 (0.47) | CCNE2CCNE1CDK2KDM4EDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | claimed |
| EP-2426130-B1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KK (JP) | 2015-03-11 | — | — | EP | claimed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | claimed |
| EP-2426130-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-03-07 | — | — | EP | claimed |
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2426130-B1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KK (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2426130-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126101-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | 全薬工業株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | CCNE2 3736/4885CCNE1 1574/4885CDK2 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.